Emergent Issues and Future Trends in Familial Adenomatous Polyposis

  • Gian Gaetano Delaini
  • Marco Scaglia
  • Gianluca Colucci
  • Tom Öresland


Familial Adenomatous Polyposis Colorectal Adenoma Adenomatous Polyposis Coli Gene Recurrent Adenoma Duodenal Adenoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bapat BV, Parker JA, Berk T et al (1994) Combined use of molecular and biomarkers for presymptomatic carrier risk assessment in familial adenomatous polyposis: implications for screening guidelines. Dis Colon Rectum 37(2):165–171PubMedCrossRefGoogle Scholar
  2. 2.
    Sporn MB (1976) Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 36:2699–2702PubMedGoogle Scholar
  3. 3.
    Gann PH, Manson JE, Glynn RJ et al (1993) Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 85:1220–1224PubMedCrossRefGoogle Scholar
  4. 4.
    Baron JA, Cole BF, Sandler RS et al (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891–899PubMedCrossRefGoogle Scholar
  5. 5.
    Sandler RS, Halabi S, Baron JA et al (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348:883–890PubMedCrossRefGoogle Scholar
  6. 6.
    Ruschoff J, Wallinger S, Dietmaier W et al (1998) Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad Sci USA 95:11301–11306PubMedCrossRefGoogle Scholar
  7. 7.
    Giardiello FM, Hamilton SR, Krush AJ et al (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313–1316PubMedCrossRefGoogle Scholar
  8. 8.
    Steinbach G, Lynch PM, Phillips RKS et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946–1952PubMedCrossRefGoogle Scholar
  9. 9.
    Narisawa T, Fukaura Y, Terada K, Sekiguchi H (1998) Prevention of N-methylnitrosourea-induced colon tumorigenesis by ursodeoxycholic acid in F344 rats. Jpn J Cancer Res 89:1009–1013PubMedGoogle Scholar
  10. 10.
    Rodrigues CM, Kren BT, Steer CJ, Setchell KD (1995) The site-specific delivery of ursodeoxycholic acid to the rat colon by sulfate conjugation. Gastroenterology 109:1835–1844PubMedCrossRefGoogle Scholar
  11. 11.
    Ikegami T, Matsuzaki Y, Shoda J et al (1998) The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue. Cancer Lett 134:129–139PubMedCrossRefGoogle Scholar
  12. 12.
    Davignon J, Laaksonen R (1999) Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 10:543–559PubMedCrossRefGoogle Scholar
  13. 13.
    Torrance CJ, Jackson PE, Montgomery E et al (2000) Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6:1024–1028PubMedCrossRefGoogle Scholar
  14. 14.
    Clapper ML, Chang WC, Meropol NJ (2001) Chemoprevention of colorectal cancer. Curr Opin Oncol 13:307–313PubMedCrossRefGoogle Scholar
  15. 15.
    Winde G, Schmid KW, Schlegel W, Fischer R, Osswald H, Bunte H (2005) Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment: advantages of a lowdose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Am J Gastroenterol 100(7):1498–1502CrossRefGoogle Scholar
  16. 16.
    de Vos tot Nederveen Cappel WH, Jarvinen HJ, Bjork J et al (2003) Worldwide survey among polyposis registries of surgical management of severe duodenal adenomatosis in familial adenomatous polyposis. Br J Surg 90(6):705–710CrossRefGoogle Scholar
  17. 17.
    Tulchinsky H, Keidar A, Goldman G et al (2005) Surgical treatment and long-term outcome of patients with familial adenomatous polyposis: 16 years experience at the Tel Aviv Sourasky Medical Center. Isr Med Assoc J 7(2):82–85PubMedGoogle Scholar
  18. 18.
    Lee J, Hargest R, Wasan H, Phillips RKS (2004) Liposome-mediated adenomatous polyposis coli gene therapy: a novel anti-adenoma strategy in multiple intestinal neoplasia mouse model. Dis Colon Rectum 47(12):2105–2113PubMedCrossRefGoogle Scholar
  19. 19.
    Bright-Thomas RM, Agrawal A, Hargest R (2002) Preclinical studies of gene transfer for the treatment of desmoid disease in familial adenomatous polyposis. Br J Surg 89(12):1563–1569PubMedCrossRefGoogle Scholar
  20. 20.
    Burke CA, Santisi J, Church J, Levinthal G (2005) The utility of capsule endoscopy small bowel surveillance in patients with polyposis. Am J Gastroenterol 100(7):1498–1502PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2006

Authors and Affiliations

  • Gian Gaetano Delaini
    • 1
  • Marco Scaglia
    • 2
  • Gianluca Colucci
    • 1
  • Tom Öresland
    • 3
  1. 1.Department of General Surgery and GastroenterologyUniversity of VeronaVeronaItaly
  2. 2.Department of SurgeryS. Luigi Gonzaga HospitalOrbassano, TurinItaly
  3. 3.Department of Surgery Colorectal UnitSahlgrenska University HospitalGöteborgSweden

Personalised recommendations